Carbonic anhydrase IX-targeted H-APBC nanosystem combined with phototherapy facilitates the efficacy of PI3K/mTOR inhibitor and resists HIF-1α-dependent tumor hypoxia adaptation | Journal of Nanobiotechnology

[ad_1]

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    PubMed 
    Article 

    Google Scholar
     

  • Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397(10286):1750–69.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Waks AG, Winer EP. Breast cancer treatment a review. JAMA J Am Med Assoc. 2019;321(3):288–300.

    CAS 
    Article 

    Google Scholar
     

  • Gong Y, Ji P, Yang YS, Xie S, Yu TJ, Xiao Y, Jin ML, Ma D, Guo LW, Pei YC. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 2021;33(2):51–64.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Nakazawa MS, Keith B, Simon MC. Oxygen availability and metabolic adaptations. Nat Rev Cancer. 2016;16(10):663–73.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Rundqvist H, Johnson RS. Tumour oxygenation: implications for breast cancer prognosis. J Intern Med. 2013;274(2):105–12.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. Cell Metab. 2018;27(2):281–98.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Schito L, Rey S. Cell-autonomous metabolic reprogramming in hypoxia. Trends Cell Biol. 2018;28(2):128–42.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Paredes F, Williams HC, San Martin A. Metabolic adaptation in hypoxia and cancer. Cancer Lett. 2021;502:133–42.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Shamis SAK, McMillan DC, Edwards J. The relationship between hypoxia-inducible factor 1 alpha (HIF-1 alpha) and patient survival in breast cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;159:103231.

    PubMed 
    Article 

    Google Scholar
     

  • Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J Cell Mol Med. 2010;14(4):771–94.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Rohani N, Hao LL, Alexis MS, Joughin BA, Krismer K, Moufarrej MN, Soltis AR, Lauffenburger DA, Yaffe MB, Burge CB, Bhatia SN, Gertler FB. Acidification of tumor at stromal boundaries drives transcriptome alterations associated with aggressive phenotypes. Cancer Res. 2019;79(8):1952–66.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671–7.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Pastorekova S, Gillies RJ. The role of carbonic anhydrase IX in cancer development: links to hypoxia, acidosis, and beyond. Cancer Metastasis Rev. 2019;38(1–2):65–77.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Becker HM. Carbonic anhydrase IX and acid transport in cancer. Br J Cancer. 2020;122(2):157–67.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Andreucci E, Peppicelli S, Carta F, Brisotto G, Biscontin E, Ruzzolini J, Bianchini F, Biagioni A, Supuran C, Calorini L. Carbonic anhydrase IX inhibition affects viability of cancer cells adapted to extracellular acidosis. J Mol Med. 2017;95(12):1341–53.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Lou YM, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Keller UAD, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT, Dedhar S. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res. 2011;71(9):3364–76.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Corbet C, Feron O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer. 2017;17(10):577–93.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Bohn T, Rapp S, Luther N, Klein M, Bruehl TJ, Kojima N, Lopez PA, Hahlbrock J, Muth S, Endo S, Pektor S, Brand A, Renner K, Popp V, Gerlach K, Vogel D, Lueckel C, Arnold-Schild D, Pouyssegur J, Kreutz M, Huber M, Koenig J, Weigmann B, Probst HC, von Stebut E, Becker C, Schild H, Schmitt E, Bopp T. Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nat Immunol. 2018;19(12):1319–29.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Qiu GZ, Jin MZ, Dai JX, Sun W, Feng JH, Jin WL. Reprogramming of the tumor in the hypoxic niche: the emerging concept and associated therapeutic strategies. Trends Pharmacol Sci. 2017;38(8):669–86.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Wigerup C, Pahlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016;164:152–69.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Xiao WK, Zhang GC, Chen B, Chen XQ, Wen LZ, Lai JG, Li XR, Li M, Liu H, Liu J, Han HZ, Lizaso A, Liao N. Mutational landscape of PI3K-AKT-mTOR pathway in breast cancer: implications for targeted therapeutics. J Cancer. 2021;12(14):4408–17.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664–71.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Land SC, Tee AR. Hypoxia-inducible factor 1 alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007;282(28):20534–43.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744–57.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960–76.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S, Rosen N. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discov. 2011;1(3):248–59.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92–111.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O’Gara S, Olowokure O, Fathallah HA. Phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. Target Oncol. 2017;12(3):323–32.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Walton ZE, Patel CH, Brooks RC, Yu YJ, Ibrahim-Hashim A, Riddle M, Porcu A, Jiang TY, Ecker BL, Tameire F, Koumenis C, Weeraratna AT, Welsh DK, Gillies R, Alwine JC, Zhang L, Powell JD, Dang CV. Acid suspends the circadian clock in hypoxia through inhibition of mTOR. Cell. 2018;174(1):72–87.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Cao Q, Zhou DJ, Pan ZY, Yang GG, Zhang H, Ji LN, Mao ZW. CAIXplatins: highly potent platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors. Angew Chem Int Ed. 2020;59(42):18556–62.

    CAS 
    Article 

    Google Scholar
     

  • Li JY, Shi KJ, Sabet ZF, Fu WJ, Zhou H, Xu SX, Liu T, You M, Cao MJ, Xu MZ, Cui XJ, Hu B, Liu Y, Chen CY. New power of self-assembling carbonic anhydrase inhibitor: short peptide-constructed nanofibers inspire hypoxic cancer therapy. Sci Adv. 2019;5(9):eaax0937.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Chen XY, Zhang HL, Zhang M, Zhao PR, Song RX, Gong T, Liu YY, He XH, Zhao KL, Bu WB. Amorphous Fe-based nanoagents for self-enhanced chemodynamic therapy by re-establishing tumor acidosis. Adv Funct Mater. 2020;30(6):1908365.

    CAS 
    Article 

    Google Scholar
     

  • Xie ZJ, Fan TJ, An J, Choi W, Duo YH, Ge YQ, Zhang B, Nie GH, Xie N, Zheng TT, Chen Y, Zhang H, Kim JS. Emerging combination strategies with phototherapy in cancer nanomedicine. Chem Soc Rev. 2020;49(22):8065–87.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Chen L, Zhou LL, Wang CH, Han Y, Lu YL, Liu J, Hu XC, Yao TM, Lin Y, Liang SJ, Shi S, Dong CY. Tumor-targeted drug and CpG delivery system for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv Mater. 2019;31(52):1904997.

    CAS 
    Article 

    Google Scholar
     

  • Zhang Y, Xu C, Yang XL, Pu KY. Photoactivatable protherapeutic nanomedicine for cancer. Adv Mater. 2020;32(34):2002661.

    CAS 
    Article 

    Google Scholar
     

  • Zhao YY, Zhang L, Chen ZX, Zheng BY, Ke MR, Li XS, Huang JD. Nanostructured phthalocyanine assemblies with efficient synergistic effect of type I photoreaction and photothermal action to overcome tumor hypoxia in photodynamic therapy. J Am Chem Soc. 2021;143:13980–9.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Li XS, Lee DY, Huang JD, Yoon JY. Phthalocyanine-assembled nanodots as photosensitizers for highly efficient type I photoreactions in photodynamic therapy. Angew Chem Int Ed. 2018;57:9885–90.

    CAS 
    Article 

    Google Scholar
     

  • Thews O, Riemann A. Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev. 2019;38(1–2):113–29.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Kumar S, Sharife H, Kreisel T, Mogilevsky M, Bar-Lev L, Grunewald M, Aizenshtein E, Karni R, Paldor I, Shlomi T, Keshet E. Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood vessel proximity. Cell Metab. 2019;30(1):201–11.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Sun X, Sun B, Dong G, Huang L, Zhang W, Zhou J, et al. Noninvasive temperature monitoring for dual-modal tumor therapy based on lanthanide-doped up-conversion nanocomposites. Biomaterials. 2019;201:42–52. https://doi.org/10.1016/j.biomaterials.2019.02.014.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Kwon N, Kim H, Li XS, Yoon JY. Supramolecular agents for combination of photodynamic therapy and other treatments. Chem Sci. 2021;12(21):7248–68.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Li XS, Kwon N, Guo T, Liu Z, Yoon JY. Innovative strategies for hypoxic-tumor photodynamic therapy. Angew Chem Int Ed. 2018;57(36):11522–31.

    CAS 
    Article 

    Google Scholar
     

  • Li XS, Lovell JF, Yoon JY, Chen XY. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17(11):657–74.

    PubMed 
    Article 

    Google Scholar
     

  • Mei SL, Xu XH, Priestley RD, Lu Y. Polydopamine-based nanoreactors: synthesis and applications in bioscience and energy materials. Chem Sci. 2020;11(45):12269–81.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • An J, Hu YG, Cheng K, Li C, Hou XL, Wang GL, Zhang XS, Liu B, Zhao YD, Zhang MZ. ROS-augmented and tumor-microenvironment responsive biodegradable nanoplatform for enhancing chemo-sonodynamic therapy. Biomaterials. 2020;234:119761.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Zhao WR, Hu XC, Zhou LL, Qiang SF, Shi S, Dong CY, et al. M2-like TAMs function reversal contributes to breast cancer eradication by combination dual immune checkpoint blockade and photothermal therapy. Small. 2021;17:2007051.

    CAS 
    Article 

    Google Scholar
     

  • Li YY, Jiang CH, Zhang DW, Chen XS, Lu LH, et al. Targeted polydopamine nanoparticles enable photoacoustic imaging guided chemo-photothermal synergistic therapy of tumor. Acta Biomater. 2017;47:124–34.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Zheng WW, Zhang HJ, Deng YM, Ji XY, Zeng XW, et al. Dual-response oxygen-generating MnO2 nanoparticles with polydopamine modification for combined photothermal-photodynamic therapy. Chem Eng J. 2020;389:124494.

    Article 
    CAS 

    Google Scholar
     

  • Huang Q, Zhang SH, Li Z, Gao MY, et al. Boosting the radiosensitizing and photothermal performance of Cu2-xSe nanocrystals for synergetic radiophotothermal therapy of orthotopic breast cancer. ACS Nano. 2019;13(2):1342–53.

    CAS 
    PubMed 

    Google Scholar
     

  • Estrella V, Chen TA, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM, Sloane BF, Johnson J, Gatenby RA, Gillies RJ. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013;73(5):1524–35.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Pillai SR, Damaghi M, Marunaka Y, Spugnini EP, Fais S, Gillies RJ. Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev. 2019;38(1–2):205–22.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Karar J, Cerniglia GJ, Lindsten T, Koumenis C, Maity A. Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1 alpha expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther. 2012;13(11):1102–11.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Iommarini L, Porcelli AM, Gasparre G, Kurelac I. Non-canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer. Front Oncol. 2017;7:286.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Masoud GN, Li W. HIF-1 alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378–89.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • LaGory EL, Giaccia AJ. The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol. 2016;18(4):356–65.

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • McGuirk S, Audet-Delage Y, St-Pierre J. Metabolic fitness and plasticity in cancer progression. Trends Cancer. 2020;6(1):49–61.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM. Emerging perspectives on mTOR inhibitor-associated pneumonitis in breast cancer. Oncologist. 2018;23(6):660–9.

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • Jiang W, Wang YF, Wargo JA, Lang FF, Kim BYS. Considerations for designing preclinical cancer immune nanomedicine studies. Nat Nanotechnol. 2021;16(1):6–15.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15(5):273–91.

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • [ad_2]

    Source link

    Leave a Reply

    Your email address will not be published.